Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trialMatteo Della Porta, Uwe Platzbecker, Sandra Kreitz et al.|The Lancet Haematology|2024Cited by 50
Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent-Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs Epoetin Alfa in the COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini et al.|Blood|2024Cited by 4
Long-Term Transfusion Independence with Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Lower-Risk Myelodysplastic Syndromes in the COMMANDS TrialGuillermo Garcia‐Manero, Uwe Platzbecker, Valeria Santini et al.|Advances in Therapy|2025Cited by 4
Clinical benefit of luspatercept in erythropoiesis-stimulating agent (ESA)-naive patients (pts) with early disease characteristics and very low-, low-, or intermediate-risk Myelodysplastic Syndromes (LR-MDS): A post hoc analysis from the commands trialValeria Santini, Amer M. Zeidan, Matteo Della Porta et al.|Blood|2025Cited by 1
Clinical Benefits of Achieving Hemoglobin (Hb) Levels ≥ 10 g/dL in Transfusion-Dependent (TD) Erythropoiesis-Stimulating Agent (ESA)-Naive Patients (Pts) with Lower-Risk (LR) Myelodysplastic Syndromes (MDS) Treated with Luspatercept in the COMMANDS TrialValeria Santini, Matteo Della Porta, Uwe Platzbecker et al.|Blood|2024Cited by 0